Quality of life and functions after chemoradiation for rectal cancer: A review of recent publications

Current Colorectal Cancer Reports

Volumn 9, Issue 2, 2013, Pages 157-167

  Gavaruzzi, Teresa ^a   Giandomenico, Francesca ^a   Pucciarelli, Salvatore ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bowel function; Chemoradiotherapy; Faecal continence; Patient reported outcomes; Quality of life; Rectal cancer; Review; Sexual function; Urinary function

Indexed keywords

BODY IMAGE; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; COHORT ANALYSIS; DEFECATION HABIT; FATIGUE; FECES INCONTINENCE; FOOD INTAKE; HEALTH CARE PRACTICE; HUMAN; INTESTINE FUNCTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RECURRENT DISEASE; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SOCIAL INTERACTION; SOCIAL STATUS; SYSTEMATIC REVIEW;

EID: 84882877566     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-013-0161-x     Document Type: Review

References (60)

1. Kosinski L, Habr-Gama A, Ludwig K, Perez R. Shifting concepts in rectal cancer management a review of contemporary primary rectal cancer treatment strategies. CA Cancer J Clin. 2012;62(3):173-202.
2. Palmer G, Martling A, Cedermark B, Holm T. Preoperative tumour staging with multidisciplinary team assessment improves the outcome in locally advanced primary rectal cancer. Colorectal Dis. 2011;13(12):1361-9.
3. Burton S, Brown G, Daniels IR, et al. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer. 2006;94(3):351-7.
4. Blazeby JM, Avery K, Sprangers M, et al. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol. 2006;24(19):3178-86.
5. Langenhoff BS, Krabbe PF, Wobbes T, et al. Quality of life as an outcome measure in surgical oncology. Br J Surg. 2001;88(5):643-52.
6. Lipscomb J, Gotay C, Snyder C. Introduction to outcome assessment in cancer. In: Outcomes assessment in cancer: measures, methods and applications. Cambridge: Cambridge University Press; 2005. p. 11-3.
7. • Hadi M, Gibbons E, Fitzpatrick R. A structured review of patient-reported outcome measures for colorectal cancer. Patient-reported Outcome Measurement Group, Department of Public Health, University of Oxford April 2010. Review of the evidence of PROs for colorectal cancer patients, distinguishing between generic, preference-based, and cancer-specific instruments.
8. Snyder C, Aaronson NK. Use of patient-reported outcomes in clinical practice. Lancet. 2009;374(9687):369-70.
9. Donaldson MS. Taking PROs and patient-centered care seriously: incremental and disruptive ideas for incorporating PROs in oncology practice. Qual Life Res. 2008;17(10):1323-30.
10. Pieterse AH, Baas-Thijssen MC, Marijnen CA, Stiggelbout AM. Clinician and cancer patient views on patient participation in treatment decision-making: a quantitative and qualitative exploration. Br J Cancer. 2008;99(6):875-82.
11. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-40.
12. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926-33.
13. Bosset J-F, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-23.
14. Gérard J-P, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancer: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620-5.
15. Engel J, Kerr J, Schleisinger-Racib A, et al. Quality of life in rectal cancer patients: a four-year prospective study. Ann Surg. 2003;238(2):203-13.
16. Neuman HB, Schrag D, Cabral C, et al. Can differences in bowel function after surgery for rectal cancer be identified by the European Organization for Research and Treatment of Cancer quality of life instruments? Ann Surg Oncol. 2007;14(5):1727-34.
17. Pietrzak L, Mujko K, Novacki MP, et al. Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomized trial. Radiother Oncol. 2007;84(3):217-25.
18. Pucciarelli S, Del Bianco P, Efficace F, et al. Health-related quality of life, faecal continence and bowel function in rectal cancer patients after chemoradiotherapy followed by radical surgery. Support Care Cancer. 2010;18(5):601-8.
19. Rauch P, Miny J, Conroy T, et al. Quality of life among disease-free survivors of rectal cancer. J Clin Oncol. 2004;22(2):354-60.
20. Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients - a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199-206.
21. • Brændengen M, Tveit KM, Hjermstad MJ, et al. Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study. Eur J Cancer. 2012;48(6):813-9. Prospective evaluation of QoL in a randomised trial, comparing pCRT and pRT and comparing results also with reference data from the general population.
22. Brændengen M, Tveit KM, Bruheim K, et al. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized phase III study. Int J Radiat Oncol Biol Phys. 2011;81(4):1017-24.
23. •• Kang SB, Park JW, Jeong SY, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of a open-label randomised controlled trial. Lancet Oncol. 2010;11(7):637-45. Prospective evaluation of QoL in a randomised trial comparing laparoscopic and open TME. Prospective study with high compliance and adequate sample size.
24. Stephens RJ, Thompson LC, Quirke P, et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol. 2010;27:4233-9.
25. Tiv M, Puyraveau M, Mineur L, et al. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. Cancer Radiother. 2010;14(6-7):530-4.
26. Canda AE, Terzi C, Gorken IB, et al. Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients. Int J Colorectal Dis. 2010;25(2):197-204.
27. How P, Stelzner S, Branagan G, et al. Comparative Quality of life in patients following abdominoperineal excision and low anterior resection for low rectal cancer. Dis Colon Rectum. 2012;55(4):400-6.
28. Kripp M, Wieneke J, Kienle P, et al. Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer - impact on long-term quality of life. Eur J Surg Oncol. 2012;38(6):472-7.
29. Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633-40.
30. Nishizawa Y, Fujii S, Saito N, et al. The association between anal function and neural degeneration after preoperative chemoradiotherapy followed by intersphinteric resection. Dis Colon Rectum. 2011;54(11):1423-9.
31. Peng J, Shi D, Goodman KA, et al. Early results of quality of life for curatively treated rectal cancer in Chinese patients with EORTC QLQ-CR29. Radiat Oncol. 2011;6:93.
32. Lupattelli M, Mascioni F, Bellavita R, et al. Long-term anorectal function after postoperative chemoradiotherapy in high-risk rectal cancer patients. Tumori. 2010;96(1):34-41.
33. •• Pucciarelli S, Del Bianco P, Efficace F, et al. Patient-Reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg. 2011;253(1):71-7. Prospective and multicentre evaluation of QoL, with several assessments, including at baseline, high compliance, and large sample size, focused on the effect of CRT treatment on QoL.
34. Aaronson NK, Ahmedzai S, Bergam B, et al. European Organisation for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76.
35. Sprangers M, Te Velde A, Aaronson N. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module. (QLQ-CR38). Eur J Cancer. 1999;35(2):238-47.
36. Whistance RN, Conroy T, Chie W, et al. European Organisation for research and treatment of Cancer Quality of Life Group. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer. 2009;45(17):3017-26.
37. Rockwood TH, Church JM, Fleshman JW, et al. Fecal incontinence quality of life scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum. 2000;43(1):9-16.
38. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30(6):473-83.
39. Prieto L, Thorsen H, Juul K. Development and validation of a quality of life questionnaire for patients with colostomy or ileostomy. Health Qual Life Outcomes. 2005;3:62.
40. Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36(1):77-97.
41. Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. Gut. 1999;44(1):77-80.
42. Temple LK, Bacik J, Savatta SG, et al. The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer. Dis Colon Rectum. 2005;48(7):1353-65.
43. Rosen RC, Riley A, Wagner G, Osterloh IH, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822-30.
44. Jensen PT, Klee M, Thranov I, Groenvold M. Validation of a questionnaire for self-assessment of sexual function and vaginal changes after gynaecological cancer. Psychooncology. 2004;13(8):577-92.
45. Brændengen M, Tveit KM, Berglund Å, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26(22):3687-94.
46. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373(9666):811-20.
47. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radio- therapy for rectal cancer: preliminary results EORTC 22921. J Clin Oncol. 2005;23(24):5620-7.
48. Bosset JF, Calais G, Daban A, et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance: Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer. 2004;40(2):219-24.
49. Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer. 2007;96(6):912-7.
50. Horisberger K, Treschl A, Mai S, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiation Oncology Biol Phys. 2009;74(5):1487-93.
51. Hofheinz R, Wenz F, Post S, et al. Capecitabine (cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): safety results of a randomized, phase III trial. J Clinical Oncol. 2009;27(15S):4014.
52. Holzer B, Matzel K, Schiedeck T, et al. Do geographic and educational factors influence the quality of life in rectal cancer patients with a permanent colostomy? Dis Col Rectum. 2005;48(12):2209-16.
53. Cornish JA, Tilney HS, Heriot AG, et al. A meta-analysis of quality of life for abdominoperineal excision of rectum versus anterior resection for rectal cancer. Ann Surg Oncol. 2007;14(7):2056-68.
54. Holzer B, Gyasi A, Schiessel R, Rosen HR. Patients' expectations of colorectal surgery for cancer. Colorectal Dis. 2006;8(3):186-91.
55. Amsterlaw J, Zikmund-Fisher BJ, Fagerlin A, Ubel PA. Can avoidance of complications lead to biased healthcare decisions? Judgment and Decision Making. 2006;1(1):64-75.
56. Bossema A, Stiggelbout A, Baas-Thijssen M, et al. Patients' preferences for low rectal cancer surgery. Eur J Surg Oncol. 2008;34(1):42-8.
57. Masya L, Young J, Solomon M, et al. Preferences for outcomes of treatment for rectal cancer: patient and clinician utilities and their application in an interactive computer-based decision aid. Dis Colon Rectum. 2009;52(12):1994- 2002.
58. Vironen J, Kairaluoma M, Aalto A, Kellokumpu I. Impact of functional results on quality of life after rectal cancer surgery. Dis Colon Rectum. 2006;49(5):568-78.
59. Sutherland HJ, Till JE. Quality of life assessments and levels of decision making: differentiating objectives. Qual Life Res. 1993;2(4):297-303.
60. Stiggelbout AM, de Haes JCJM. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol. 2001;19(1):220-30.